Skip to search form
Skip to main content
Semantic Scholar's Logo
You are currently offline. Some features of the site may not work correctly.
National Institutes of Health
250 ML sipuleucel-T 200000 CELLS/ML Injection [Provenge]
Provenge Injectable Product
sipuleucel-T Injection [Provenge]
Semantic Scholar uses AI to extract papers important to this topic.
Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy
Expert review of vaccines
Corpus ID: 207196186
Cancer immunotherapy has recently emerged as an important treatment modality. FDA approval of provenge, ipilimumab and…
Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.
U. A. Ndefo
P & T : a peer-reviewed journal for formulary…
Corpus ID: 8104960
Therapies for prostate cancer depend on age, rate of the cancer’s growth, the specific benefits and drawbacks of treatment, and…
Approval of provenge seen as first step for cancer treatment vaccines.
Journal of the National Cancer Institute
Corpus ID: 33468632
Adecade in development, Dendreon’s prostate cancer vaccine, sipuleucelT (Provenge), has become the first therapeutic cancer…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE